Verition Fund Management
LGND icon

Verition Fund Management’s Ligand Pharmaceuticals LGND Stock Holding History

Verition Fund Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,863
Closed -$861K – 3742
2025
Q3 		$861K Sell
4,863
-9,306
-66% -$1.38M ﹤0.01% 2644
2025
Q2 		$1.61M Buy
+14,169
New +$1.51M 0.01% 2109
2025
Q1 		– Sell
-5,876
Closed -$630K – 3534
2024
Q4 		$630K Sell
5,876
-85
-1% -$9.61K ﹤0.01% 2334
2024
Q3 		$597K Buy
+5,961
New +$600K ﹤0.01% 2220
2023
Q4 		– Sell
-5,321
Closed -$319K – 2530
2023
Q3 		$319K Buy
+5,321
New +$350K ﹤0.01% 1694
2019
Q1 		– Sell
-3,184
Closed -$270K – 1223
2018
Q4 		$270K Buy
+3,184
New +$339K 0.02% 654

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Verition Fund Management's LGND Position: Q4 2025 in Review

Verition Fund Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 4,863 shares — an estimated $861K sold.

Verition Fund Management first reported a position in LGND in Q4 2018 and held it in 6 quarters. The position peaked at $1.61M in Q2 2025. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Verition Fund Management reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 4,863 Ligand Pharmaceuticals shares in Q4 2025, an estimated $861K.
  • Verition Fund Management first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 6 quarters.
  • Verition Fund Management's Ligand Pharmaceuticals position peaked at $1.61M in Q2 2025.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.